REG - IQ-AI Limited - Board Changes

IQ-AIAnnouncement

19/11/2024 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241119:nRSS8206Ma&default-theme=true

RNS Number : 8206M  IQ-AI Limited  19 November 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Board Changes

 

IQ-AI Appoints Renowned Brain Tumor Champion to Board of Directors

 

 

IQ-AI Ltd (LSE: IQAI) is pleased to announce the appointment of Dr. Al
Musella, MD, as a Non-Execuitve Director. Dr. Musella brings almost three
decades of experience as founder and president of the Musella Foundation for
Brain Tumor Research and Information, Inc.

Dr. Musella formed the first online support group for brain tumor patients in
1993, which has since evolved into the compreshensive resource website,
virtualtrials.org (http://www.virtualtrials.org) . Under his leadership, the
Musella Foundation has made many significant contributions to the brain tumor
community including funding novel research, advocating for the approval of new
treatments, and helping patients access needed treatments with financial
support.

Dr Musella has issued more than $19.3 million in brain tumor research grants
and co-payment assistance grants to help patients access needed treatments. He
also advocated for FDA and Medicare approval for Optune, Temodar, Gliadel,
Gleolan, Avastin and  many other treatments. His current efforts include
lobbying for the "Promising Pathway Act," legislation that accelerates the
clinical trial approval process in order to move new drugs to market more
efficiently.

"We are pleased to welcome Dr. Musella to our Board of Directors," said Trevor
Brown, CEO of IQ-AI. "His extensive network and experience will be invaluable
as we forge ahead in the development of oral gallium maltolate and build upon
our core imaging business".

Dr. Musella commented, "I am honored to join IQ-AI and the Imaging Biometrics
team, and I look forward to contributing to their efforts of helping brain
tumor patients and the clinicians who support them".

No information is required to be disclosed pursuant to paragraph 9.6.13R of
the Listing Rules.

 As part of these Board Changes, Vinod Kaushal will step down as
non-executive director with immediate effect.

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Tel: 020 7220 9797

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms
and therapeutics that transform how clinicians diagnose and treat patients
more efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABBBDBDDBDGSC